JACK NIELSEN

Jack Nielsen is a distinguished Partner at Vivo Capital, a global healthcare investment firm renowned for its strategic focus on life sciences. Since joining Vivo Capital in 2007, Mr. Nielsen has been instrumental in shaping the firm's investment strategy and portfolio growth, particularly within the dynamic biotechnology, pharmaceutical, and medical device sectors. His extensive experience encompasses a broad spectrum of investment stages, from early-stage venture capital to growth equity and public market opportunities, reflecting a deep understanding of the healthcare ecosystem.

At Vivo Capital, Mr. Nielsen's responsibilities include deal sourcing, due diligence, transaction execution, and active portfolio management. He leverages his profound industry knowledge to identify innovative companies with high growth potential, guiding them through critical development phases. His investment philosophy is centered on supporting companies that are developing groundbreaking therapies and technologies designed to address significant unmet medical needs and improve patient outcomes. This commitment is evident in his involvement with numerous successful ventures.

Before his tenure at Vivo Capital, Mr. Nielsen honed his investment acumen at several reputable firms. He served as a Director at Baystar Capital, where he focused on healthcare investments, further solidifying his expertise in the sector. Prior to Baystar, he was an Associate at HealthCare Ventures, a well-regarded venture capital firm, gaining valuable experience in early-stage life sciences investing. Mr. Nielsen began his professional career as a management consultant at LEK Consulting, where he specialized in the healthcare and life sciences industries, providing strategic advice to a diverse range of clients. This foundational experience equipped him with a robust analytical framework and a comprehensive understanding of market dynamics.

Mr. Nielsen's educational background further underpins his success. He earned his Master of Business Administration from Harvard Business School, a testament to his strong business acumen. He also holds a Bachelor of Arts in Economics from Northwestern University. His academic achievements, combined with his extensive professional experience, position him as a thought leader in healthcare investment.

Throughout his career, Jack Nielsen has been involved with numerous notable investments, demonstrating his ability to identify and nurture promising companies. These include his board roles or significant contributions to companies such as Aclaris Therapeutics, BioAtla, Harmony Biosciences, Impel Pharmaceuticals, KalVista Pharmaceuticals, LumiraDx, Marinus Pharmaceuticals, Reata Pharmaceuticals, Sierra Oncology (acquired by GSK), Spruce Biosciences, Sutro Biopharma, Vaxcyte, and Zymeworks. His strategic guidance has helped many of these companies achieve significant milestones, from successful clinical trials to market entry and strategic exits, ultimately delivering value to both investors and patients. His work at Vivo Capital continues to drive innovation and growth within the global healthcare landscape.